Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-acting beta2-agonists for chronic obstructive pulmonary disease.

S Appleton1, B Smith, A Veale

  • 1Dept. of Medicine, The Queen Elizabeth Hospital, Woodville Rd., Woodville, Adelaide, AUSTRALIA, 5011. sappleto@medicine.adelaide.edu.au

The Cochrane Database of Systematic Reviews
|May 5, 2000
PubMed
Summary

Long-acting beta2-agonists offer modest lung function improvements for COPD patients. A 50 mcg dose of salmeterol significantly reduced breathlessness and improved quality of life in one study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Sleep apnea syndrome: Clinical, polygraphic, and treatment outcomes profiles in Cotonou].

Revue des maladies respiratoires·2025
Same author

Irish General Practitioner referrals to psychological therapies.

Irish journal of psychological medicine·2018
Same author

The effect of vitamin D supplementation on knee osteoarthritis, the VIDEO study: a randomised controlled trial.

Osteoarthritis and cartilage·2016
Same author

UK management practices in stage I seminoma and the Medical Research Council Trial of Imaging and Schedule in Seminoma Testis managed with surveillance.

Clinical oncology (Royal College of Radiologists (Great Britain))·2011
Same author

Providing patients with reviews of evidence about COPD treatments: a controlled trial of outcomes.

Chronic respiratory disease·2006
Same author

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease.

The Cochrane database of systematic reviews·2006

Area of Science:

  • Pulmonology
  • Pharmacology
  • Clinical Trials

Background:

  • Chronic obstructive pulmonary disease (COPD) involves partially reversible airflow limitation.
  • Long-acting beta2-agonists (LABAs) are used for asthma and recommended for COPD.
  • Evaluating LABA effectiveness and side effects in COPD is crucial due to cost and potential risks.

Purpose of the Study:

  • To assess the effectiveness of long-acting beta2-adrenoceptor agonists in COPD patients.
  • To determine improvements in lung function, quality of life, and reduction in dyspnea.
  • To evaluate the impact of salmeterol and formoterol on COPD management.

Main Methods:

  • Conducted a systematic search of the Cochrane Airways Group register and bibliographies of identified RCTs.

Related Experiment Videos

  • Included randomized controlled trials (RCTs) over four weeks comparing LABAs (salmeterol, formoterol) with placebo in stable COPD patients.
  • Measured outcomes including FEV1, PEFR, symptom scores, 6-minute walk distance, quality of life, Borg scores, and rescue bronchodilator use.

    • Main Results:

    • Four RCTs involving salmeterol were included; two were 16-week parallel studies, two were 4-week cross-over studies.
    • Salmeterol (50 mcg and 100 mcg twice daily) showed significant increases in FEV1 in 16-week studies (WMD 0.10-0.12 L).
    • A 50 mcg dose of salmeterol twice daily significantly improved disease-specific quality of life (St. George's Respiratory Questionnaire) and reduced breathlessness (Borg score < 3).

    Conclusions:

    • Long-acting beta2-agonists provide only minor increases in FEV1 for COPD patients.
    • A specific dose (salmeterol 50 mcg twice daily) demonstrated clinically significant improvements in quality of life and reduced breathlessness.
    • Further research may be needed to fully elucidate the benefits and optimal use of LABAs in COPD management.